Gut Health

Crohn’s disease (CD) and ulcerative colitis (UC) are the major forms of inflammatory bowel disease (IBD) in developed nations such as Australia. It is common for a patient’s symptoms to first appear while they are in their 30s, although these diseases can affect children and older adults. IBD is a chronic illness and the symptoms, including diarrhoea, rectal bleeding, and abdominal pain, have a significant impact on quality of life.

The origin of IBD is not well understood, but the most favoured theory is that a genetically at-risk individual encounters a single or series of environmental triggers that lead to disease. Discovery of the first susceptibility gene for CD (called NOD2) and its proposed role in the body, support this hypothesis. The Gut Health Group is currently investigating several other genes for links to IBD.

Both CD and UC are characterised by a series of relapses and remissions. There is limited understanding of the clinical, environmental and genetic factors that may influence how severe the disease is or how often it recurs. The Gut Health Group is analysing a broad range of factors in a large cohort of IBD patients.

CURRENT RESEARCH

  • identification of genes associated with Crohn’s disease and ulcerative colitis
  • the role of paneth cells in ileal Crohn’s Disease
  • determination of disease-specific gene expression signatures
  • incidence and prevalence of inflammatory bowel disease in South-East Queensland
  • a research project looking into the causes of inflammatory bowel disease

Staff

  • Dr Anton Lord, Research Officer
  • Katherine Hanigan, Research Assistant
  • Krupa Krishnaprasad, Research Assistant
  • Dr James Irwin, Visiting Scientist
  • Abigail Marsh, Student
  • Rina Kumar, Student

Internal Collaborators

External Collaborators

  • Associate Professor Jane Andrews, Royal Adelaide Hospital
  • Associate Professor Peter Bampton, Flinders Medical Centre
  • Professor Judy Cho, Yale University
  • Dr James Doecke, CSIRO Mathematical and Information Sciences
  • Professor Timothy Florin, Mater Medical Research Institute
  • Associate Professor Rick Duerr, University of Pittsburgh, USA
  • Dr Richard Gearry, University of Otago, New Zealand
  • Dr David Hansen, CSIRO Mathematical and Information Sciences
  • Dr Flavia Huygens, Queensland University of Technology
  • Professor Michael Kamm, St Vincent’s Hospital
  • Professor Ian Lawrence, Fremantle Hospital
  • Associate Professor Rupert Leong, Concord Hospital
  • Associate Professor Peter Lewindon, Royal Children’s Hospital and Health Services
  • Associate Professor Michael McGuckin, Mater Medical Research Institute
  • Dr Gillian Mahy, Townsville Hospital
  • Dr Miles Parkes, Addenbrookes Hospital, UK
  • Dr Rebecca Roberts, University of Otago, New Zealand
  • Dr Alissa Walsh, St Vincent’s Hospital
  • National Health and Medical Research Council
  • Royal Brisbane and Women’s Research Foundation
  • Smart State Health and Medical Research Fund
  • Abbott Australasia
  • Crohn’s and Colitis Australia
  • Orphan Australia
  • Ferring Australia
  • Pharmatel-Fresenius-Kabi

We offer a comprehensive screening of Nudix hydrolase 15 (NUDT15) variants which includes the *2,*3,*6 and *9 alleles.

The *3 NUDT15 variant that is strongly associated with thiopurine-related myelosuppression is more commonly found in East Asians and Hispanics. Testing for *3 allele only is also available. Please indicate in the test request form your preferred screen.

Test Name

NUDT15 genotyping

Turnaround time

1-3 weeks

Test method

PCR and Sanger Sequencing

Indications of use

To predict potential toxicity to thiopurine drugs (Azathioprine, 6-MP and 6-TG)

Sample required

1 EDTA tube of blood

To order the test please download the test request and clinical information sheet from below

Test request form NUDT15 Clinical information

For further enquires please email to guthealth@qimrberghofer.edu.au